Positive Phase III data set stage for UMN/Astellas flu vaccine submission
This article was originally published in Scrip
Executive Summary
Based on what they say are encouraging results from two Phase III trials in Japan, the Japanese bioventure UMN Pharma and partner Astellas are making concrete plans for a regulatory submission in the country for a cell cultured seasonal influenza vaccine.